Korea S.E.
23:00:00 13/06/2024 BST
5-day change
1st Jan Change
2,830
KRW
+4.43%
-0.70%
-52.12%
Platform Partners Asset Management Co., Ltd. acquired 11.18% stake in MG MED, Inc..
Platform Partners Asset Management Co., Ltd. acquired 11.18% stake in MG MED, Inc. (KOSDAQ:A180400) on November 16, 2016. Platform Partners Asset Management Co., Ltd. acquired 0.23 million shares of MG MED, Inc.
Platform Partners Asset Management Co., Ltd. completed the acquisition of 11.18% stake in MG MED, Inc. (KOSDAQ:A180400) on November 16, 2016.
Malaysian Genomics Resource Forge Strategic Alliance with South Korean Healthcare Solutions Provider
06-10
MT
Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS
12-20
CI
Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers
27/06/23
CI
Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors
13/06/23
CI
Dx & Vx Co., Ltd. agreed to acquire Avixgen, Inc. from Renaissance Asset Management, Nouveau International Co., Ltd., Lee Mi-ja, Seo Jin - young, Kim Jae-hyun , Cho Il-hyun,Park So -yeon, Jeong Ja -woon, Kim Young- ju, Yang Young-jin, Kim Hye -min and Um In-kyung for KRW 9.2 billion.
23/05/23
CI
DxVx Appoints Kevin Kwon as New President
16/05/23
CI
DxVx Appoints Yong Gu Lee as CEO
16/05/23
CI
Dx & Vx Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
13/04/23
CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors.
06/04/23
CI
Dx & Vx Co., Ltd. announced that it has received KRW 17 billion in funding
05/10/22
CI
Dx & Vx Co., Ltd. completed the acquisition of Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok.
03/10/22
CI
Dx & Vx Co., Ltd. agreed to acquire Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok for approximately KRW 15 billion.
14/09/22
CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 1.78 billion in funding
06/09/22
CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 20 billion in funding
29/08/21
CI
Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding
28/06/20
CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 999.99252 million in funding
17/06/20
CI
D S and partners limited company cancelled the acquisition of 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd..
28/04/20
CI
Cancer Rop Holdings Co., Ltd. cancelled the acquisition of 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund.
10/07/19
CI
Ds&Partners signed a contract to acquire 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd. for KRW 7.5 billion.
28/04/19
CI
Resort Savers, Inc. Announces Medical Distribution Partnership with South Korea based CancerROP
16/07/18
CI
GI Innovation, Inc. announced that it has received KRW 4.999995 billion in funding from Cancer Rop Co., Ltd.
12/07/18
CI
Cancer Rop Holdings Co., Ltd. singed a contract to acquire 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund for approximately KRW 9.5 billion.
10/07/18
CI
GI Innovation, Inc. announced that it expects to receive KRW 4.999995 billion in funding from Dx & Vx Co., Ltd.
27/06/18
CI
Cancer Rop Co., Ltd. announced that it has received KRW 10 billion in funding
12/04/18
CI
Oxford Vacmedix UK Limited announced that it has received KRW 13.28575 billion in funding from Cancer Rop Co., Ltd.
05/03/18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Dx & Vx Co Ltd, formerly Cancer Rop Co Ltd, is a Korea-based company primarily engaged in the molecular diagnosis business. The Molecular Diagnosis Business segment is engaged in the manufacture and sale of deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) chips and other products. manufacture and sale of diagnostic reagents used for molecular diagnosis, and various enzymes and experimental reagents used for biological research.
More about the company
1st Jan change
Capi.
-52.12% 61.8M -43.39% 7.73B +11.68% 3.7B +0.37% 2.28B -21.21% 1.99B -23.77% 1.6B +18.25% 739M -10.04% 687M -36.12% 461M -4.47% 279M
Bio Diagnostics & Testing
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DX & VX CO., LTD. 